Intercept Pharmaceuticals, Inc. is looking to real-world evidence, and potentially a Phase III trial with a fixed-dose combination, to help secure Ocaliva’s (obeticholic acid) current indication in primary biliary cholangitis now that the company has decided to discontinue development in nonalcoholic steatohepatitis (NASH) fibrosis.
Following receipt of a second US Food and Drug Administration complete response letter for obeticholic acid (OCA), a farnesoid X...








